Smith & Nephew plc SNN
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position can be maintained pending clearer signs of stabilisation in US orthopaedics.
Weak underlying growth and leadership vacuum outweigh buyback support and attractive valuation near yearly lows.
The market is characterised by frustration over repeated guidance cuts and leadership uncertainty following the CFO departure.
HOLD is the call. Negative is the market mood. Medium risk means some things can go wrong.
Latest change
- 5 Nov 2026 — Update shows weaker growth outlook after lowered full-year guidance, driven by ongoing US ortho weakness.
About the company
Smith & Nephew develops, manufactures and distributes medical devices for repair, regeneration and replacement of soft and hard tissue. The company operates in three segments: Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Operations are global with primary listing on the London Stock Exchange and ADR on NYSE.
Bull case
Share buybacks, new product launches and stable cash flow provide support near yearly lows.
Bear case
Lowered growth guidance, CFO departure and weakness in US orthopaedics create uncertainty.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| US orthopaedics sales | Continued weakness in knee and hip implants → further guidance cuts and lower trading profit. | Stabilisation or recovery in US knee → confirmation of 4 percent growth guidance and higher margins. |
| CFO appointment | Prolonged vacancy → increased turnaround uncertainty and lower investor confidence. | Rapid hiring of experienced CFO → strengthened confidence in RISE strategy execution. |
Why this signal
Weak underlying growth and leadership vacuum outweigh buyback support and attractive valuation near yearly lows.
Recent news
Q3 trading update on 4 November showed revenue of USD 1.551 billion (+3.4 % underlying). Full-year guidance was lowered to around 3 % growth and free cash flow of approximately USD 750 million. Talks with Johnson & Johnson on an orthopaedics merger have ended without a deal. The LANDMARK knee system received FDA clearance and first procedures have been completed. The share price rose 7.56 % to USD 32.46 on the report day.